Detalles de la búsqueda
1.
Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer.
Bioorg Med Chem Lett
; 23(7): 1945-8, 2013 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23466225
2.
Small-molecule androgen receptor downregulators as an approach to treatment of advanced prostate cancer.
Bioorg Med Chem Lett
; 21(18): 5442-5, 2011 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-21782422
3.
Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Bioorg Med Chem Lett
; 18(6): 1799-803, 2008 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18313293
4.
A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Bioorg Med Chem Lett
; 18(2): 674-8, 2008 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-18061446
5.
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models.
Cancer Res
; 76(20): 6084-6094, 2016 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27550455
6.
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).
J Med Chem
; 59(17): 7801-17, 2016 09 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27528113
7.
AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1-Mutant Breast Tumors in Preclinical Models.
Cancer Res
; 76(11): 3307-18, 2016 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27020862
8.
Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist.
J Med Chem
; 58(20): 8128-40, 2015 Oct 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-26407012
9.
Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor.
J Med Chem
; 57(20): 8249-67, 2014 Oct 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-25271963
10.
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors.
ACS Med Chem Lett
; 4(8): 742-6, 2013 Aug 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24900741
11.
AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo.
Mol Cancer Ther
; 12(9): 1715-27, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23861347
12.
Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Bioorg Med Chem Lett
; 17(22): 6326-9, 2007 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17869514
13.
Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.
Bioorg Med Chem Lett
; 16(6): 1633-7, 2006 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16380259
14.
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
Bioorg Med Chem Lett
; 16(18): 4908-12, 2006 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-16806916
15.
5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.
Bioorg Med Chem Lett
; 15(19): 4226-9, 2005 Oct 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16055332
16.
Cancer
Berlin, Heidelberg; Springer Berlin
Heidelberg;Imprint: Springer; 2007. 451 p.
Monografía
en Inglés
| Bibliografia | ID: bib-348599
Resultados
1 -
16
de 16
1
Próxima >
>>